{"doi":"10.1016/s0140-6736(20)30552-3","title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","abstract":"BACKGROUND: Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. METHODS: In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. FINDINGS: Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 m","journal":"The Lancet","year":2020,"id":49189,"datarank":7.053656268957725,"base_score":5.648974238161206,"endowment":5.648974238161206,"self_citation_contribution":0.847346135724181,"citation_network_contribution":6.2063101332335435,"self_endowment_contribution":0.847346135724181,"citer_contribution":6.2063101332335435,"corpus_percentile":null,"corpus_rank":null,"citation_count":283,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9456,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02453308"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":236300,"name":"Rupam Tripura","orcid":"0000-0002-3281-9702","position":1,"is_corresponding":false},{"id":236301,"name":"Richard M. Hoglund","orcid":"0000-0002-5322-912X","position":2,"is_corresponding":false},{"id":236302,"name":"Aung Pyae Phyo","orcid":"0000-0002-0383-9624","position":3,"is_corresponding":false},{"id":238857,"name":"Dysoley Lek","orcid":null,"position":4,"is_corresponding":false},{"id":238858,"name":"Akhter ul Islam","orcid":null,"position":5,"is_corresponding":false},{"id":238859,"name":"Anupkumar R. Anvikar","orcid":null,"position":6,"is_corresponding":false},{"id":238860,"name":"Parthasarathi Satpathi","orcid":null,"position":7,"is_corresponding":false},{"id":236303,"name":"Sanghamitra Satpathi","orcid":"0000-0003-0519-6199","position":8,"is_corresponding":false},{"id":236304,"name":"Prativa Kumari Behera","orcid":"0000-0002-5435-3325","position":9,"is_corresponding":false},{"id":238861,"name":"Amar Tripura","orcid":null,"position":10,"is_corresponding":false},{"id":236305,"name":"Subrata Baidya","orcid":"0000-0003-3465-593X","position":11,"is_corresponding":false},{"id":236306,"name":"Marie A. Onyamboko","orcid":"0000-0002-7501-5931","position":12,"is_corresponding":false},{"id":236307,"name":"Nguyễn Hoàng Châu","orcid":"0000-0002-7826-3850","position":13,"is_corresponding":false},{"id":238862,"name":"Yok Sovann","orcid":null,"position":14,"is_corresponding":false},{"id":238863,"name":"Seila Suon","orcid":null,"position":15,"is_corresponding":false},{"id":238864,"name":"Sokunthea Sreng","orcid":null,"position":16,"is_corresponding":false},{"id":238865,"name":"Sivanna Mao","orcid":null,"position":17,"is_corresponding":false},{"id":238866,"name":"Savuth Oun","orcid":null,"position":18,"is_corresponding":false},{"id":238867,"name":"Sovannary Yen","orcid":null,"position":19,"is_corresponding":false},{"id":238868,"name":"Chanaki Amaratunga","orcid":null,"position":20,"is_corresponding":false},{"id":238869,"name":"Kitipumi Chutasmit","orcid":null,"position":21,"is_corresponding":false},{"id":238870,"name":"Chalermpon Saelow","orcid":null,"position":22,"is_corresponding":false},{"id":238871,"name":"Ratchadaporn Runcharern","orcid":null,"position":23,"is_corresponding":false},{"id":238872,"name":"Weerayuth Kaewmok","orcid":null,"position":24,"is_corresponding":false},{"id":238873,"name":"Nhu Thi Hoa","orcid":null,"position":25,"is_corresponding":false},{"id":238874,"name":"Ngo Viet Thanh","orcid":null,"position":26,"is_corresponding":false},{"id":236308,"name":"Borimas Hanboonkunupakarn","orcid":"0000-0001-8729-1442","position":27,"is_corresponding":false},{"id":236309,"name":"James J. Callery","orcid":"0000-0002-3218-2166","position":28,"is_corresponding":false},{"id":236310,"name":"D. Mohanty","orcid":"0000-0002-9790-4000","position":29,"is_corresponding":false},{"id":238875,"name":"James Heaton","orcid":null,"position":30,"is_corresponding":false},{"id":236311,"name":"Myo Thant","orcid":"0000-0002-3696-5977","position":31,"is_corresponding":false},{"id":236312,"name":"Kripasindhu Gantait","orcid":"0000-0001-8484-5489","position":32,"is_corresponding":false},{"id":238876,"name":"Tarapada Ghosh","orcid":null,"position":33,"is_corresponding":false},{"id":236313,"name":"Roberto Amato","orcid":"0000-0001-8633-9221","position":34,"is_corresponding":false},{"id":90057,"name":"Richard D. Pearson","orcid":"0000-0002-7386-3566","position":35,"is_corresponding":false},{"id":238877,"name":"Christopher G. Jacob","orcid":null,"position":36,"is_corresponding":false},{"id":236314,"name":"Sónia Gonçalves","orcid":"0000-0003-0321-3303","position":37,"is_corresponding":false},{"id":236315,"name":"Mavuto Mukaka","orcid":"0000-0002-5036-6583","position":38,"is_corresponding":false},{"id":236316,"name":"Naomi Waithira","orcid":"0000-0002-2267-9347","position":39,"is_corresponding":false},{"id":236317,"name":"Charles J. Woodrow","orcid":"0000-0002-5134-7165","position":40,"is_corresponding":false},{"id":236318,"name":"Martin P. Grobusch","orcid":"0000-0002-0046-1099","position":41,"is_corresponding":false},{"id":236319,"name":"Michèle van Vugt","orcid":"0000-0001-8365-2482","position":42,"is_corresponding":false},{"id":238878,"name":"Rick M. Fairhurst","orcid":null,"position":43,"is_corresponding":false},{"id":236320,"name":"Phaik Yeong Cheah","orcid":"0000-0001-6327-3266","position":44,"is_corresponding":false},{"id":236321,"name":"Thomas J. Peto","orcid":"0000-0003-3197-9891","position":45,"is_corresponding":false},{"id":236322,"name":"Lorenz von Seidlein","orcid":"0000-0002-0282-6469","position":46,"is_corresponding":false},{"id":236323,"name":"Mehul Dhorda","orcid":"0000-0002-7849-3293","position":47,"is_corresponding":false},{"id":236324,"name":"Richard J. Maude","orcid":"0000-0002-5355-0562","position":48,"is_corresponding":false},{"id":236325,"name":"Markus Winterberg","orcid":"0000-0002-8529-9317","position":49,"is_corresponding":false},{"id":236326,"name":"Thuy-Nhien Nguyen","orcid":"0000-0002-4101-5706","position":50,"is_corresponding":false},{"id":33751,"name":"Dominic Kwiatkowski","orcid":"0000-0002-5023-0176","position":51,"is_corresponding":false},{"id":238879,"name":"Mallika Imwong","orcid":null,"position":52,"is_corresponding":false},{"id":236327,"name":"Podjanee Jittamala","orcid":"0000-0002-1020-2760","position":53,"is_corresponding":false},{"id":238880,"name":"Khin Lin","orcid":null,"position":54,"is_corresponding":false},{"id":238881,"name":"Tin Maung Hlaing","orcid":null,"position":55,"is_corresponding":false},{"id":236328,"name":"Kesinee Chotivanich","orcid":"0000-0002-6533-6811","position":56,"is_corresponding":false},{"id":236329,"name":"Rekol Huy","orcid":"0000-0001-8552-3369","position":57,"is_corresponding":false},{"id":236330,"name":"Caterina Fanello","orcid":"0000-0003-1932-9562","position":58,"is_corresponding":false},{"id":236331,"name":"Elizabeth A. Ashley","orcid":"0000-0002-7620-4822","position":59,"is_corresponding":false},{"id":236332,"name":"Mayfong Mayxay","orcid":"0000-0002-6056-4516","position":60,"is_corresponding":false},{"id":236333,"name":"Paul N. Newton","orcid":"0000-0002-4608-6431","position":61,"is_corresponding":false},{"id":62203,"name":"Tran Tinh Hien","orcid":"0000-0002-6271-3298","position":62,"is_corresponding":false},{"id":238882,"name":"Neena Valecha","orcid":null,"position":63,"is_corresponding":false},{"id":236334,"name":"Frank Smithuis","orcid":"0000-0002-4704-9915","position":64,"is_corresponding":false},{"id":236335,"name":"Sasithon Pukrittayakamee","orcid":"0000-0003-2573-3967","position":65,"is_corresponding":false},{"id":238883,"name":"Abul Faiz","orcid":null,"position":66,"is_corresponding":false},{"id":236336,"name":"Olivo Miotto","orcid":"0000-0001-8060-6771","position":67,"is_corresponding":false},{"id":236337,"name":"Joel Tärning","orcid":"0000-0003-4566-4030","position":68,"is_corresponding":false},{"id":236338,"name":"Nicholas Day","orcid":"0000-0003-2309-1171","position":69,"is_corresponding":false},{"id":236339,"name":"Nicholas J. White","orcid":"0000-0002-1897-1978","position":70,"is_corresponding":false},{"id":236340,"name":"Arjen M. Dondorp","orcid":"0000-0001-5190-2395","position":71,"is_corresponding":false},{"id":236299,"name":"Rob W. van der Pluijm","orcid":"0000-0002-7040-5447","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-18T20:36:25.163232Z","pmid":"32171078","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}